drugset / Trial / NCT04848558

A Study of Nipocalimab in Healthy Male and Female Participants

NCT04848558

Phase 1 Completed 89 enrolled Janssen Research & Development, LLC
RandomizedSequentialDouble-blindOther

Summary

The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of nipocalimab following subcutaneous (SC) administration compared with intravenous (IV) administration in healthy participants.

Timeline

Start
2021-05-25
Primary completion
2022-05-26
Completion
2022-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Nipocalimab Monoclonal antibody Intravenous

Indications

No indication recorded.